Collaboration Funding Innovation Press Release Regulatory
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Investment Press Release
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Diversity Hemex Team
HEMEX contribution for preparing tomorrow's leaders!
Continue reading
Investment Press Release
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Hemex Team
Noémie is a student at FMS Muttenz. She completed a two-week internship at HEMEX focusing [...]
Continue reading
Our portfolio company Opterion Health AG announced today the successful agreement of a EUR 8.4m Bridge Financing
Round. The proceeds from this financing round will be used to complete preclinical activities and prepare for entry into Phase I. Heartfelt congratulations on your success, Opterion!
Starting on the 21st of January 2021 and during the next three months, we have organized exclusive online webinars with plenty of interesting opportunities just for you!
Learn how can you lay the groundwork for the clinical development of your product with our Contract Research Organization
The New Year is an exciting time as we all focus on goals and resolutions. At HEMEX, we are focused on bringing you solutions at each critical step of the clinical development of your product. Together we can generate the accurate evidence needed for success!
This year has been unlike any other, but at HEMEX we have continued with a positive spirit through it all. In this article, we want to take a look back at 2020 as we look ahead to all that we can accomplish next year.
2020 has turned our lives upside down. It started as an exciting yea
In times of high uncertainty like this 2020 year, it is necessary to celebrate and savor the victories. We want to congratulate our portfolio company Sleepiz for its well-deserved success in winning collaboration with one of the three Executive MBA cohorts at the beginning of 2021
Our portfolio company ASPIVIX SA announced last week the completion of and interim analysis results from its Phase I first-in-women trial. The two-phase ADVANCE Women trial is assessing the usability, efficacy, and safety of the investigational CAREVIX, the innovative device designed as a modern and gentler alternative. Warmest congratulations on your achievement, ASPIVIX!
